Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study

Archives of Internal Medicine

Volumn 158, Issue 9, 1998, Pages 1021-1031

  Rogers, Sharon L ^a   Doody, Rachelle S ^a   Mohs, Richard C ^a   Friedhoff, Lawrence T ^a  

^a EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EDEMA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; TREATMENT OUTCOME; UNITED STATES;

EID: 0032507788     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.9.1021     Document Type: Article

References (38)

1. Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. 6th ed, Baltimore, Md: Williams & Wilkins; 1995:2562.
2. Giacobini E. Pharmacotherapy of Alzheimer disease: new drugs and novel strategies. Prog Brain Res. 1993;98:447-454.
3. Davis RE, Doyle PD, Carroll RT, Emmerling MR, Jaen J. Cholinergic therapies for Alzheimer's disease. Arzneimittetforschung Drug Res. 1995;45:425-431.
4. Davis P, Maloney AJ, Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
5. Cardozo MG, limura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. QSAR analysis of the substituted inanone and benzylpiperidine rings of a series of indanonebenzylpiperidine inhibitors of acetylcholinesterase. J Med Chem. 1992;35:584-589.
6. Cardozo MG, Kawai T, limura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. Conformational analysis and molecular shape comparisons of a series of indanonebenzylpiperidine inhibitors of acetylcholinesterase. J Med Chem., 1992;35:590-601.
7. Sugimoto H, limura Y, Yamanishi Y, Yamatsu K. Synthesis and anticholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-l-indanone-2-yl) methyl] piperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett. 1992;2:871-876.
8. Sugimoto H, Tsuchiya Y, Sugumi H, et al. Novel piperidine derivatives: synthesis and anti-cholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyt] piperidine derivatives. J Med Chem. 1990;33:1880-1887.
9. Rogers SL, Yamansihi Y, Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. Boston, Mass: Birkhäuser: 1991:314-320.
10. Sugimoto H, Tsuchiya Y, Sugumi H, et al. Synthesis and structure activity relationships of acetylcholinesterase inhibitors of 1-benzyl-4-(2-phthalimidoethyl) piperidine and related derivatives. J Med Chem. 1992;35:4542-4548.
11. Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.
12. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Garcon SI, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
13. Farlow M, Garcon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA. 1992;268:2523-2529.
14. Taylor P. Anticholinesterase agents. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed. New York, NY: McGraw-Hill Book Co; 1993:131-149.
15. Sherman K. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. In: Becker R, Giacobini E, eds. Cholinergic Basis forAlzheimer Therapy. Boston, Mass: Birkhäuser; 1991:321-328.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
18. Folstein MF, Folstein SE, McHugh PR, "Mini-Mental State": a practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res. 1975;12:189-198.
19. Hughes CD, Berg L, Danziger L, Coben LA, Martin RL. A new rating scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
20. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
21. Schneider LS, Olin JT, Doody RS, et al, and the Alzheimer's Disease Cooperative Study. Validity and reliability of the Alzheimer's Disease Cooperative StudyClinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11 (suppl 2):S22-S32.
22. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type: 4 evaluations of intervention. Ann Neurol. 1992;31:242-249.
23. Blau TH. Quality of life, social indicators and criteria of change. Prof Psychol. 1977;8:464-473.
24. Lee JW, Rogers SL, Friedhoff LT, Cooper NM. Validation and application of an HPLC method for the determination of 1 -benzyl-4-[(5,6-dimethoxy-1 -indanon)-2-yl] methyl piperidine HCI (E2020) in human plasma. Pharm Res. 1992;9:S350,
25. Hulse JD, Rogers SL, Friedhoff LT, Sukovaty R, Pedersen JE, Lee JW. A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl. Pharm Res. 1992;9:S228.
26. Neter J, Wasserman W, Kutner M. Applied Linear Statistical Models. Homewood, III: Richard D Irwin Inc; 1990.
27. 2 tests, Biometrics. 1954;10:417-451.
28. Bross IDJ. How to use RIDIT analysis. Biometrics. 1958;14:18-38.
29. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Epidemiology and Biostatistics. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. Washington, DC: US Food and Drug Administration; 1993. Publication PB93-209138.
30. Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer's type in the Framingham Study. Neurology. 1992;42:115-119.
31. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
32. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390-396.
33. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of the course of Alzheimer's disease patients in a longitudinal study: a preliminary report. Psychopharmacol Bull. 1988:24:458-462.
34. Thai LJ, Maasur DM, Fuld PA, Sharpless NS, Davies P. Memory improvement with oral physostigmine and lecithin in Alzheimer's disease. In: Katzman R, ed. Banbury Report: Biological Aspects of Alzheimer's Disease. 9th ed. New Haven, Conn: Cold Spring Harbor Laboratory; 1983;15:461-470.
35. Becker R, Colliver J, Elble R, et al. Effects of metrifonate, a long acting cholinesterase inhibitor in Alzheimer's disease: report of an open trial. Drug Dev Res. 1990;19:425-434.
36. Antouno PG, for the Mentane Study Group. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: a double-blind, placebocontrolled study. Arch Intern Med. 1995;155:1766-1772.
37. Harrell LE, Jope RS, Falgout J, et al. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease. JAm Geriatr Soc. 1990;38:113-122.
38. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract. 1996;8:1-8.